A detailed history of Tower Research Capital LLC (Trc) transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 11,154 shares of SMMT stock, worth $80,754. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,154
Previous 21,144 47.25%
Holding current value
$80,754
Previous $55,000 16.36%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.55 - $5.07 $25,474 - $50,649
-9,990 Reduced 47.25%
11,154 $46,000
Q4 2023

Feb 13, 2024

BUY
$1.67 - $2.83 $24,021 - $40,706
14,384 Added 212.78%
21,144 $55,000
Q3 2023

Nov 14, 2023

BUY
$1.54 - $2.42 $2,861 - $4,496
1,858 Added 37.9%
6,760 $12,000
Q2 2023

Aug 14, 2023

SELL
$1.32 - $2.81 $21,083 - $44,881
-15,972 Reduced 76.52%
4,902 $12,000
Q1 2023

May 09, 2023

SELL
$1.38 - $5.41 $8,564 - $33,574
-6,206 Reduced 22.92%
20,874 $36,000
Q4 2022

Feb 10, 2023

BUY
$0.68 - $5.31 $10,668 - $83,308
15,689 Added 137.73%
27,080 $115,000
Q3 2022

Nov 10, 2022

BUY
$0.89 - $1.63 $1,804 - $3,305
2,028 Added 21.66%
11,391 $14,000
Q2 2022

Aug 15, 2022

BUY
$0.92 - $2.38 $4,772 - $12,345
5,187 Added 124.21%
9,363 $9,000
Q1 2022

May 12, 2022

BUY
$2.0 - $3.45 $190 - $327
95 Added 2.33%
4,176 $10,000
Q4 2021

Feb 14, 2022

BUY
$2.45 - $5.64 $4,218 - $9,712
1,722 Added 73.0%
4,081 $11,000
Q3 2021

Nov 15, 2021

SELL
$4.83 - $8.27 $5,201 - $8,906
-1,077 Reduced 31.34%
2,359 $12,000
Q2 2021

Aug 16, 2021

SELL
$5.15 - $8.46 $7,112 - $11,683
-1,381 Reduced 28.67%
3,436 $26,000
Q1 2021

May 17, 2021

BUY
$5.17 - $11.19 $5,345 - $11,570
1,034 Added 27.33%
4,817 $28,000
Q4 2020

Feb 16, 2021

BUY
$3.25 - $6.0 $12,294 - $22,698
3,783 New
3,783 $18,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $1.46B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.